United States: Cannabis In Animal Supplements: A Hazy Proposition

Over at our Life Sciences Decoded blog, we have discussed the state of limbo in which animal dietary supplements exist from a regulatory perspective. In the case of human products, foods, dietary supplements and drugs occupy three different regulatory areas, each with its own requirements, manufacturing standards and premarket application needs. Each also has unique regulatory systems. Food has HARPC and FSMA, drugs have generic versions and extraordinarily complex and expensive premarket approval requirements, and dietary supplements have unique labeling requirements. This is largely because of the Dietary Supplement Health and Education Act of 1994 (DSHEA) which delineated supplements from regular food products and from drugs designed to cure diseases.

The same delineation does not apply to products made for animal consumption. In 1996, and echoed in 2002, the FDA stated that DSHEA does not apply to products for animals. As a result, the FDA treats all products for animals as one of three main products:

  • Animal feed is defined as an article for food or animal consumption.
  • A feed additive is typically any substance which is expected to become a component of animal food either as an ingredient or by top dressing a feed or placement in the animal's water.
  • A drug is defined as an article intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease. This includes Medicated Type A articles and the products derived from them, called medicated feeds.

A look at the animal supplement market reveals products similar to those products found in the human dietary supplement markets – products intended to affect or support a structure or function of the body. These products do not meet the definitions of a feed, feed additive or drug. Without the application of DSHEA, the result has been, to date, a virtually unregulated market.

Cannabis and animal products

The question, therefore, is what should the cannabis industry do when considering the production of cannabis-based supplement products for animals? What FDA regulation should these industry members expect? Last year, Life Sciences Decoded predicted that the majority of these animal supplement products would likely be considered foods and fall under the control of the FDA's new rules under the Food Safety Modernization Act (FSMA). This means they will be subject to significant oversight and regulatory requirements. Life Sciences Decoded covered the basics of these regulatory regimes generally but more specifically as they apply to animal products and include:

  • Hazard Analysis and Risk-based Preventive Controls (HARPC) for animal foods
  • The Sanitary Transport of Human and Animal Food

The question then becomes, will cannabis products meant for animals be treated as a food or drug by the FDA? The first and foremost place to look is, of course, the FDA. However, despite cannabis' continued Schedule I classification in the case of human uses, the FDA has been relatively silent on the use of cannabis in animal products. The closest the FDA has come to addressing the issue is a series of 2015 warning letters to members of the cannabis industry. Of those letters, one was directed toward Canna-Pet, LLC for four of its products aimed at dogs and cats. In this letter, the FDA determined that Canna-Pet's products were drugs under 21 U.S.C. § 321 (g)(1)(B) which defines a drug as "articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals."

In finding that the products were drugs, the FDA looked to Canna-Pet's own marketing claims related to these products, which included:

  • Antitumor, Antiepileptic, Anticancer, Anti-inflammatory, Bone stimulant, Analgesic, Anti-depressant, Antibacterial, Antipsoriatic, Antidiabetic, . . . Anti-nausea, Anti-anxiety, . . . Antipsychotic, . . . Immunosuppressive.
  • We Recommend Canna-Pet" as a daily food additive for all pets, but especially for those with arthritis, allergies, anxiety or behavior issues, compromised immune systems, diabetes, digestive issues, nausea, chronic pain, cancer, seizures, and those receiving palliative care.

The important distinction for the cannabis industry is that the FDA labeled Canna-Pet products as drugs not because they contained cannabis or cannabis extracts, but because the Canna-Pet products were, "intended to mitigate, treat, or prevent disease in animals, it is a drug." Under 21 U.S.C. §§ 360b, 360ccc and 360ccc-1, new animal drug products must be approved pursuant to a new animal drug application, the subject of a conditionally approved new animal drug application, or an index listing, respectively. Without these approvals, the FDA will find products for animals meeting the definition of a drug to be unsafe and adulterated under the FDCA. This means the FDA has the ability to issue warning letters, obtain injunctions against the sale of the products, and seize the products.

Impact of the Cole Memorandum and the Rohrabacher-Farr medical marijuana amendment

Currently, there are limitations as to how the federal government can pursue enforcement actions against members of the cannabis industry. Two major federal government actions are responsible for these limitations. First, the document known as the "Cole Memorandum," previously discussed here on Tracking Cannabis, is a statement by the Department of Justice (DOJ) that it will not pursue charges against individuals involved in, or participating in, the cannabis industries in states where there are rigorous and enforced regulatory systems to control cannabis products. In 2014, Congress passed the Rohrabacher-Farr medical marijuana amendment that stated:

None of the funds made available in this Act to the Department of Justice may be used, with respect to [states with cannabis legalization statutes] to prevent such States from implementing their own State laws that authorize the use, distribution, possession, or cultivation of medical marijuana.

Many in the industry see this as a free pass for cannabis businesses to operate without federal interference. Nothing could be further from the truth. First, the Rohrabacher-Farr amendment and Cole Memorandum apply only to medical cannabis programs, and do not apply to recreational cannabis use. Second, they only apply to the Department of Justice, and therefore its enforcement actions involving cannabis activities. This is a narrow set of activities the federal government cannot partake in, and generally does not apply to the FDA and its administrative or civil activities. In addition, to the foregoing, there is great concern over how the new administration will continue to view cannabis, particularly in light of the nomination of Jeff Sessions for U.S. Attorney General.

The prime example of this are the warning letters the FDA sent to members of the industry in 2015 and 2016. These letters represent meaningful enforcement actions against the cannabis industry, and these letters were spawned by a significant number of activities and situations. For example, one of the products that led to the Canna-Pets letters described above, despite advertising itself as CBD product, contained no cannabis or cannabis extracts at all. In addition, while no such actions have occurred yet, there is little reason why other federal agencies (such as the FTC regulating misleading advertising) could not regulate the cannabis industry.

Industry impact

What does this mean for members of the cannabis industry looking to produce products for animals? First, understanding that marketing terminology matters is key to positioning products not as drugs, but rather as foods or feeds not subject to the premarket approval process and clinical trial requirements for animal drugs.

Regulatory counsel can review your marketing and ensure that your products avoid making drug-like claims ("treats epilepsy" or "anti-tumor"). Second, avoiding classification as a drug is the first step to avoiding the FDA's enforcement activities. The second is ensuring that your internal processes meet all applicable regulatory requirements. This may include having a compliant food safety plan; an understanding of your suppliers not just of active ingredients but other ingredients and even packaging as well; and managing the safe and sanitary transportation of ingredients and finished products.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions